

UCSF

UC San Francisco Previously Published Works

Title

Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.

Permalink

<https://escholarship.org/uc/item/7pj5d56p>

Journal

PloS one, 11(11)

ISSN

1932-6203

Authors

Peyser, Noah D
Pendleton, Kelsey
Gooding, William E
et al.

Publication Date

2016

DOI

10.1371/journal.pone.0166185

Peer reviewed

RESEARCH ARTICLE

Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer

Noah D. Peyser¹, Kelsey Pendleton², William E. Gooding³, Vivian W. Y. Lui⁴, Daniel E. Johnson⁵, Jennifer R. Grandis^{1*}

1 Department of Otolaryngology—Head and Neck Surgery, University of California San Francisco, San Francisco, CA, United States of America, 94143, **2** Department of Otolaryngology, University of Pittsburgh and the University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States of America, 15213, **3** Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States of America, 15213, **4** Department of Pharmacology and Pharmacy, School of Biomedical Sciences, Li-Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China, **5** Department of Medicine, University of Pittsburgh and the University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States of America

* Jennifer.Grandis@ucsf.edu



OPEN ACCESS

Citation: Peyser ND, Pendleton K, Gooding WE, Lui VWY, Johnson DE, Grandis JR (2016) Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS ONE 11(11): e0166185. doi:10.1371/journal.pone.0166185

Editor: Sumitra Deb, Virginia Commonwealth University, UNITED STATES

Received: July 27, 2016

Accepted: October 24, 2016

Published: November 17, 2016

Copyright: © 2016 Peyser et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are from The Cancer Genome Atlas and are available through the data matrix: <https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm>.

Funding: This work was supported by the National Cancer Institute (NIH) R01CA077308 and the American Cancer Society CRP-13-308-06-COUN to JRG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

Background

Hyperactivation of STAT3 via constitutive phosphorylation of tyrosine 705 (Y705) is common in most human cancers, including head and neck squamous carcinoma (HNSCC). STAT3 is rarely mutated in cancer and the (epi)genetic alterations that lead to STAT3 activation are incompletely understood. Here we used an unbiased approach to identify genomic and epigenomic changes associated with pSTAT3(Y705) expression using data generated by The Cancer Genome Atlas (TCGA).

Methods and Findings

Mutation, mRNA expression, promoter methylation, and copy number alteration data were extracted from TCGA and examined in the context of pSTAT3(Y705) protein expression. mRNA expression levels of 1279 genes were found to be associated with pSTAT3(Y705) expression. Association of pSTAT3(Y705) expression with caspase-8 mRNA expression was validated by immunoblot analysis in HNSCC cells. Mutation, promoter hypermethylation, and copy number alteration of any gene were not significantly associated with increased pSTAT3(Y705) protein expression.

Conclusions

These cumulative results suggest that unbiased approaches may be useful in identifying the molecular underpinnings of oncogenic signaling, including STAT3 activation, in HNSCC. Larger datasets will likely be necessary to elucidate signaling consequences of infrequent alterations.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is a common and frequently lethal cancer. Recent studies have elucidated the genetic landscape of HNSCC and demonstrated that mutational activation of oncogenic drivers is uncommon in HNSCC. [1–3] The number of mutations in an individual tumor ranged from 3 to 1433 with a median of 103 in a recent report from The Cancer Genome Atlas (TCGA). [3] This genomic heterogeneity underscores the challenges in developing targeted molecular therapies for HNSCC treatment. To date, the epidermal growth factor receptor-directed monoclonal antibody cetuximab is the only molecularly targeted agent that is FDA-approved for the treatment of HNSCC, though clinical responses to cetuximab remain modest and predictive biomarkers are undefined. [4] Examination of oncogenic signaling pathways rather than any single genetic variant may be of use to elucidate the molecular underpinnings of HNSCC. [5,6] Among the most common signaling aberrations in HNSCC is constitutive activation of signal transducer and activator of transcription-3 (STAT3).

STAT proteins comprise a family of transcription factors that transmit cytokine and growth factor stimuli from cell surface receptors to the nucleus, leading to induction of a wide array of genes involved in a multitude of normal and oncogenic cellular functions. Seven members of the STAT protein family have been identified: STAT1-4, STAT5a, STAT5b, and STAT6, each of which contains a DNA binding domain, a Src-homology 2 (SH2) domain, and a key tyrosine residue that is essential for activation. [7] Phosphorylation of STAT3 on tyrosine 705 (Y705) leads to robust pathway activation, and pSTAT3(Y705) expression represents a surrogate marker for active STAT3 signaling. STATs were first implicated in mammalian cell oncogenesis when Src oncogene-transformed cells were found to express constitutively active STAT3. [8] Furthermore, STAT3 activation has been identified as a requirement for Src-mediated transformation [9], and constitutively active STAT3 was found to mediate transformation of immortalized fibroblasts, leading to the recognition of STAT3 as a bona fide oncoprotein. [10] Aberrant activation of STAT3 has been detected in a variety of cancers, including breast, ovarian, prostate, multiple myeloma, leukemias, lymphomas, and HNSCC, among others. [11]

Although many upstream kinases that activate STAT3 via Y705 phosphorylation have been defined, the genetic alterations associated with constitutive STAT3 phosphorylation and activation in HNSCC remain incompletely understood. The detailed information amassed by The Cancer Genome Atlas (TCGA) provides an opportunity to interrogate the alterations that are associated with increased expression of phospho-proteins assessed in The Cancer Proteome Atlas (TCPA), including pSTAT3(Y705), in an unbiased manner. In the present study, we analyzed TCGA and TCPA data to identify genetic or epigenetic alterations, including somatic mutation, promoter methylation, mRNA expression, and copy number alteration, which are associated with elevated pSTAT3(Y705) expression in HNSCC in order to identify events that contribute to STAT3 activation in this malignancy.

Methods

Computational Analyses and Statistics

HNSCC tumor data were retrieved from The Cancer Genome or Proteome Atlas. Our cohort contained 206 HNSCC primary tumors with expression analysis of 200 proteins and phospho-proteins, including pSTAT3(Y705), as assessed by reverse phase protein array (RPPA). For each tumor, whole exome sequencing, DNA methylation (Illumina Infinium HM450 assay), mRNA expression (RNASeq V2), and copy number alteration (Affymetrix SNP 6.0 array,

interpreted using the GISTIC algorithm) data were retrieved from the TCGA Data Matrix. RPPA data were retrieved from The Cancer Proteome Atlas. [12]

Categorical variables (mutation and hypermethylation) were analyzed using Wilcoxon tests to assess a difference in pSTAT3(Y705) expression between mutated/hypermethylated compared with wild-type/non-hypermethylated. As previously described, hypermethylation was defined as a level of methylation for a genetic locus that is at least three standard deviations greater than the mean methylation of the same locus in organ-matched normal tissue as determined by the TCGA. [13] For continuous variables such as mRNA expression, Spearman's correlation test was used to establish whether mRNA expression and pSTAT3(Y705) protein expression were correlated. For copy number alteration, an ordinal variable, a two-tailed Jonckheere-Terpstra statistic was calculated for each region. For all studies a false discovery rate (FDR) < 0.1 was considered significant. Expected false discovery rates were based on the q value [14] and were computed with the R package qvalue. [15]

Cells, Reagents, and Immunoblotting

UMSCC-47 cells (obtained from Dr. Thomas E. Carey, University of Michigan) stably expressing WT caspase-8 or vector control were grown in Dulbecco's Modified Eagle's Medium (Corning, Corning, NY, USA) supplemented with 10% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA, USA), 500 µg/mL G418 (Life Technologies, Carlsbad, CA, USA), and 100 units/mL penicillin/streptomycin (Life Technologies). Western blotting was performed with standard methodology. Primary antibodies were directed against pSTAT3(Y705), total STAT3, and caspase-8 (Cell Signaling Technology, Danvers, MA) and were normalized to β-tubulin (Abcam, Cambridge, MA) loading control. Densitometry was performed using ImageJ software.

Results

Patient Characteristics

206 primary HNSCC tumors with available pSTAT3(Y705) RPPA data were included in this study (Table 1). Most tumors presented at an advanced stage (64.7% clinical stage III-IV) and were located in the oral cavity (66.0%) or larynx (28.2%). A history of smoking and/or heavy drinking was common (83.5% and 60.7%, respectively). A small number of tumors in this collection were associated with human papilloma virus (HPV) infection (14/200, 7.0%).

pSTAT3(Y705) Expression was not Associated with Clinical Characteristics at Presentation. RPPA data for pSTAT3(Y705) were retrieved from TCGA and the distribution across 206 tumors was determined (Fig 1). For these tumors, the pSTAT3(Y705) RPPA scores, presented in log₂ scale, were generally normally distributed with a median of -0.01875 and range from -1.306 to 1.2934. Using univariate analyses, pSTAT3(Y705) protein expression was analyzed with respect to the clinical characteristics summarized in Table 1. No significant difference in pSTAT3(Y705) expression was detected in relation to age, smoking, alcohol consumption, HPV infection, tumor stage, nodal stage, or primary tumor site, suggesting little or no association between clinical characteristics at presentation and STAT3 pathway activation in HNSCC.

mRNA Expression of Many Genes was Associated with pSTAT3(Y705) Expression.

Protein expression of pSTAT3(Y705) was next analyzed with respect to mRNA expression in HNSCC tumors for 14,789 genes using Spearman's correlation test. Messenger RNA expression of 1279 of these genes was found to significantly correlate with pSTAT3(Y705) protein expression ($q < 0.1$) (Fig 2 and S1 Table). The majority of the observed correlations were positive (919/1279, 71.9%), with an increase in pSTAT3(Y705) expression associated with an

Table 1. Patient characteristics of 206 HNSCC tumors with RPPA and WES results.

Characteristics	WES Tumors (n = 206)	
Age, years		
Median±SD	62	±12.3
Sex, N (%)		
Male	149	72.3%
Female	57	27.7%
Risk Factors, N (%)		
Smoking history	172	83.5%
Alcohol history	125	60.7%
HPV infection*	14	7.0%
Tumor Stage, N (%)**		
T1	12	6.1%
T2	58	29.3%
T3	50	25.3%
T4a	78	39.4%
T4b	0	0.0%
Nodal Stage, N (%)***		
N0	71	43.3%
N1	21	12.8%
N2a	4	2.4%
N2b	43	26.2%
N2c	25	15.2%
Primary tumor site, N (%)		
Oral Cavity	136	66.0%
Oropharynx	11	5.3%
Hypopharynx	1	0.5%
Larynx	58	28.2%

*N = 200 tumors assessed for HPV infection.

**N = 198 patients with tumor stage data.

***N = 164 patients with nodal stage data.

doi:10.1371/journal.pone.0166185.t001

increase in mRNA expression of the given gene. All correlations were found to be of modest magnitude, with *CX3CR1*, which codes for the CX3C chemokine receptor 1, exhibiting the strongest positive correlation with pSTAT3(Y705) ($\rho = 0.361$; [S1 Fig](#)). While *CX3CR1* has been detected in a subset of HNSCC cell lines [16], its oncogenic contribution is largely undetermined. We therefore further filtered statistically significant findings using the COSMIC Cancer Gene Census [17] to prioritize associations of high biological interest. We identified 51 known cancer genes for which mRNA expression significantly correlated with pSTAT3(Y705) expression in HNSCC tumors ([S2 Table](#)), of which 88.2% (45/51) were positive correlations. Among these, the greatest absolute correlation coefficient value detected was 0.35 for *STAT3*, indicating that *STAT3* mRNA overexpression may contribute to increased STAT3 phosphorylation in HNSCC ([Fig 3](#)). This finding suggests that our unbiased analysis is sufficiently robust to identify gene expression patterns that are likely to affect pSTAT3(Y705) expression in HNSCC.

We next sought to evaluate the biologic plausibility of a representative significant association that was mechanistically unexpected. Of particular interest was the observed correlation between caspase-8 mRNA expression and pSTAT3(Y705) expression ($\rho = 0.283$, $p = 5.8E-$




Fig 1. Distribution of pSTAT3(Y705) RPPA scores in HNSCC. The frequency distribution (A) or cumulative frequency (B) of pSTAT3(Y705) normalized RPPA protein expression was plotted for 206 HNSCC tumors. The median for these data was -0.01875 and the range from -1.306 to 1.2934.

doi:10.1371/journal.pone.0166185.g001

05). Constitutive STAT3 activation inhibits apoptosis. Therefore, it was surprising that expression of a pro-apoptotic gene was associated with pro-oncogenic STAT3 signaling. Furthermore, the *CASP8* gene is altered in 16% of HNSCC tumors (9% of which are mutated) according to The Cancer Genome Atlas. [3] To validate the association between pSTAT3 (Y705) and caspase-8 mRNA expression HNSCC cells engineered to overexpress caspase-8 and corresponding vector-transfected controls were analyzed by immunoblot. As shown in Fig 4, stable overexpression of caspase-8 in UMSCC-47 cells was associated with a corresponding increase in pSTAT3(Y705) expression, indicating that our unbiased *in silico* findings may




Fig 2. mRNA expression of 1279 genes significantly correlates with pSTAT3(Y705) protein expression. A positive correlation between mRNA expression and pSTAT3(Y705) expression was observed for 919 genes, while a negative correlation was observed for 360 genes.

doi:10.1371/journal.pone.0166185.g002




Fig 3. pSTAT3(Y705) expression correlates with STAT3 mRNA expression. Spearman's test indicates a significant correlation between *STAT3* mRNA expression and pSTAT3(Y705) protein expression ($p = 6.63 \times 10^{-7}$, correlation = 0.35).

doi:10.1371/journal.pone.0166185.g003

accurately predict unexpected biology. Interestingly, pSTAT3(Y705) expression also strongly correlated with expression of caspase-10 mRNA (S1 Table and S1 Fig). Caspase-8 and -10 are structurally closely related and both act as initiator caspases in the extrinsic apoptosis pathway. The correlation of pSTAT3(Y705) expression with both caspase-8 and -10 hints at a novel functional interaction between STAT3 signaling and mediators of the extrinsic apoptosis pathway.

Low Frequency Somatic Mutations were Not Associated with pSTAT3 (Y705) Expression

We next sought to identify individual genes whose non-synonymous mutation was associated with increased pSTAT3(Y705) expression. Of 14,596 genes analyzed, 7,984 exhibited non-




Fig 4. Caspase-8 overexpression is associated with increased pSTAT3(Y705) expression in HNSCC cells. Lysates from UMSCC-47 cells stably expressing caspase-8 or the corresponding vector control were harvested and analyzed for pSTAT3(Y705) expression by immunoblot analysis. The experiment was performed thrice with similar results.

doi:10.1371/journal.pone.0166185.g004

silent mutations in at least 2 HNSCC tumors and were included for further analysis. We then applied Student's t-test to compare pSTAT3(Y705) expression in wild-type versus mutant tumors for each of these genes and found significant differences for 242 genes ($q < 0.1$; Table 2). Further analysis indicated that these apparent significant findings are artifacts of low mutation frequency for each gene, indicating insufficiency of the t-test for these data (S2 Fig). We alternatively applied the non-parametric Wilcoxon test and found no genes for which somatic mutation was significantly associated with pSTAT3(Y705) expression (defined as $q < 0.1$; Table 2).

Table 2. Cumulative number of significant results for 7984 genes with 2 or more somatic mutations.

Test	< 0.0001	< 0.001	< 0.01	< 0.025	< 0.05	< 0.1	< 1
Student's T							
<i>p</i> value	137	196	313	451	604	907	7984
<i>q</i> value	89	106	155	180	202	242	7984
Wilcoxon							
<i>p</i> value	0	0	34	151	447	939	7944
<i>q</i> value	0	0	0	0	0	0	7802

doi:10.1371/journal.pone.0166185.t002

Promoter Methylation and Copy Number Alteration were not Associated with pSTAT3(Y705) Expression

Finally, we examined whether promoter hypermethylation or copy number alteration of any gene or region is significantly associated with increased pSTAT3(Y705) expression. We observed no significant differences in pSTAT3(Y705) protein expression upon hypermethylation of 7,286 genes (S3 Fig), or copy number alteration of 4,309 regions.

Discussion

STAT3 is frequently hyperactivated by Y705 phosphorylation in HNSCC and other cancers. The determination of somatic alterations that lead to constitutive STAT3 pathway activation may allow for the identification of predictive biomarkers of response to drugs that target STAT3 signaling. In a subset of cancer types, activating mutations of upstream kinases lead to persistent STAT3 pathway activation and predict response to kinase inhibition. Well-characterized examples include the *BCR-ABL* translocation in Philadelphia chromosome-positive leukemias, which confers sensitivity to the ABL tyrosine kinase inhibitor imatinib [18–20], as well as *epidermal growth factor receptor* (*EGFR*)-mutant lung cancers, which are sensitive to EGFR inhibition. [21–25] Additional studies have identified unexpected and low frequency gene mutations that may also lead to pSTAT3(Y705) overexpression, including somatic mutation of *NDUFA13* (encoding GRIM-19; Gene associated with Retinoid Interferon-induced Mortality-19) [26] or *GNAS* (encoding the $G_{\alpha s}$ subunit). [27]

Herein we sought to identify the alterations that are associated with STAT3 pathway activation in HNSCC. Activating kinase mutations are infrequent in HNSCC, indicating that such mutations are unlikely to be of predictive value in this disease, with the notable exception of *PIK3CA* mutation. [6] Instead, recent efforts have investigated the contribution of loss-of-function of negative regulators of STAT3, especially receptor-like protein tyrosine phosphatases. [5,13,28] To date, most efforts have focused on defining phenotypes associated with relatively narrow gene families or pathways of interest in a hypothesis-driven manner, limiting the power to identify associations that would otherwise be unanticipated. For example, previous studies in other cancers have focused on correlations between known pathway components [29], a relatively narrow set of proteins/phospho-proteins [30], and/or make use of only one data type (eg: RNA-Seq). [31] More recent efforts at integrating -omics data for identification of targetable signaling modules have taken divergent approaches, including by multiple hypothesis testing as described here. [32] To our knowledge, a cross-platform and genome-wide search for unexpected alterations that may correlate with increased pSTAT3(Y705) expression in HNSCC has not been reported.

The present study was undertaken to identify putative genomic or epigenomic alterations that lead to STAT3 activation via Y705 phosphorylation in HNSCC. While STAT3 may be alternatively activated by serine 727 (S727) phosphorylation in certain contexts [33,34], the

absence of an antibody targeting pSTAT3(S727) in the TCGA array prevents unbiased correlative analysis of this site. Our cohort comprised an atypical North American HNSCC population, in which oral cavity cancers were overrepresented (66%) and oropharyngeal cancers underrepresented (5%). pSTAT3(Y705) expression was not statistically associated with any clinical parameters analyzed including age, sex, tumor site, tumor stage, HPV, smoking, or drinking. We next analyzed mRNA expression data available from TCGA and found that expression of 1279 genes significantly correlated ($q < 0.1$) with pSTAT3(Y705) protein expression, with the majority of these (919/1279; 71.9%) being positively correlated. Of these, *CX3CR1*, which codes for the CX3C chemokine receptor 1, exhibited the strongest positive correlation with pSTAT3(Y705) ($\rho = 0.36$), though *CX3CR1* is not included in the COSMIC Cancer Gene Census. Interestingly, *CX3CR1* and *STAT3* have been reported to positively cooperate in modulating the immune interaction between monocytes and smooth muscle cells, indicating this observed signal may be tumor cell-autonomous. [35,36] When we further filtered using the COSMIC Cancer Gene Census, we found that expression of 51 known cancer genes is associated with pSTAT3(Y705) expression, with *STAT3* mRNA demonstrating the strongest positive correlation ($\rho = 0.35$) among them. We and others have previously demonstrated that *STAT3* overexpression is an early event in HNSCC carcinogenesis, where *STAT3* is upregulated and constitutively activated in cancer patients relative to healthy controls. [37] Furthermore, *STAT3* expression is associated with disease stage, nodal status, tumor size, relapse-free survival, and overall survival in early-stage oral SCC. [38] While it was unsurprising to detect a correlation between *STAT3* mRNA and *STAT3* pathway activation, we observed an unexpected correlation between pSTAT3(Y705) and *caspase-8* expression ($\rho = 0.28$), as well as *caspase-10* expression ($\rho = 0.34$). We sought to validate the *caspase-8*/pSTAT3(Y705) relationship in HNSCC cells and observed that exogenous overexpression of *caspase-8* led to marked upregulation of pSTAT3(Y705) expression. We observed no upregulation of total *STAT3* following overexpression of *caspase-8*, indicating that *STAT3* mRNA overexpression and *caspase-8* overexpression may be independent mechanisms of pSTAT3(Y705) upregulation. While it has been demonstrated that *STAT3* inhibition leads to *caspase-8*-mediated apoptosis in several model systems [39–41], non-canonical *caspase-8* signaling may alternatively lead to activation of NF- κ B signaling [42], a pathway that exhibits extensive cross-talk with *STAT3*. [43] These findings suggest that this type of analysis may uncover unanticipated biology that contributes to oncogenic signaling.

We next analyzed whole exome sequencing data from the TCGA to identify any individual genes for which non-synonymous mutation was statistically associated with *STAT3* activation in HNSCC tumors. When applying Student's t-test, we found many mutant genes with an apparent statistical association with pSTAT3(Y705) expression. Subsequent analysis indicated these were due to inappropriate application of the t test (2/206, $< 1\%$ in several cases), and a failure to screen low-frequency mutations. Application of the more appropriate Wilcoxon test failed to identify any significant association between somatic mutation and pSTAT3(Y705) expression (defined as $q < 0.1$). These findings indicate first that caution should be taken when interrogating large -omics data sets for identification of putative biomarkers, and secondly that larger cohorts will be required to identify downstream signaling consequences of infrequent alterations.

Promoter methylation or copy number alteration represent additional prominent mechanisms underlying oncogenic signaling in HNSCC. [44,45] We found that neither promoter hypermethylation nor copy number alteration for any individual gene was correlated with pSTAT3(Y705) expression, suggesting little direct contribution of gene silencing to *STAT3* pathway overactivation. Alternatively, this may indicate that our methodology is too stringent to detect effects of these particularly complex biologic events. For example, we recently

reported that promoter hypermethylation of the *PTPRT* gene is strongly associated with down-regulation of *PTPRT* mRNA, which in turn is associated with pSTAT3(Y705) overexpression. [13] In the present study, the absence of a direct statistically significant correlation between *PTPRT* methylation and pSTAT3(Y705) expression may be reflective of the noise and complexity of the many additional biologic steps between these two events rather than a true lack of association. Nevertheless, our analyses implicate many alterations, especially somatic mutation or alteration of mRNA expression, as potential mechanisms of STAT3 pathway activation in HNSCC. Further investigation may ultimately lead to deeper understanding of HNSCC biology as well as the identification of putative biomarkers of response to STAT3 inhibitors.

Supporting Information

S1 Fig. Spearman correlations for the 12 genes for which mRNA is most highly correlated with pSTAT3(Y705) expression. $q < 0.005$ for all depicted.
(TIF)

S2 Fig. Apparent significant T tests suggesting correlation between somatic mutations and pSTAT3(Y705) expression are artifacts of low mutation frequency for any single gene.
(TIF)

S3 Fig. Hypermethylation of individual genes does not significantly correlate with pSTAT3(Y705) expression. A tail strength analysis indicates a lack of significant correlation between hypermethylation of any individual gene analyzed and pSTAT3(Y705) expression.
(TIF)

S1 Table. mRNA expression correlates with STAT3 phosphorylation for 1279 genes.
(XLSX)

S2 Table. mRNA expression of known cancer genes significantly correlates with pSTAT3 (Y705) protein expression. Genes are listed in order of descending rho value. Upregulation or downregulation for each indicated gene denotes the percentage of tumors with mRNA expression greater or less than two standard deviations from the mean (Z-score), respectively. Bars indicate relative up/downregulation frequency across genes.
(XLSX)

Acknowledgments

This work was supported by the National Cancer Institute (NIH) R01CA077308 and the American Cancer Society CRP-13-308-06-COUN to JRG.

Author Contributions

Conceptualization: VWYL JRG.

Data curation: KP WEG.

Formal analysis: WEG.

Funding acquisition: JRG.

Investigation: NP KP.

Methodology: KP WEG.

Project administration: NP JRG.

Resources: DEJ JRG.

Supervision: JRG.

Visualization: NP WEG.

Writing – original draft: NP KP.

Writing – review & editing: DEJ JRG.

References

1. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. *Science* 333: 1157–1160. doi: [10.1126/science.1208130](https://doi.org/10.1126/science.1208130) PMID: [21798893](https://pubmed.ncbi.nlm.nih.gov/21798893/)
2. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* 333: 1154–1157. doi: [10.1126/science.1206923](https://doi.org/10.1126/science.1206923) PMID: [21798897](https://pubmed.ncbi.nlm.nih.gov/21798897/)
3. Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 517: 576–582. doi: [10.1038/nature14129](https://doi.org/10.1038/nature14129) PMID: [25631445](https://pubmed.ncbi.nlm.nih.gov/25631445/)
4. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, et al. (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. *Annals of Oncology* 22: 1078–1087. doi: [10.1093/annonc/mdq588](https://doi.org/10.1093/annonc/mdq588) PMID: [21048039](https://pubmed.ncbi.nlm.nih.gov/21048039/)
5. Lui VWY, Peyser ND, Ng PK-S, Hritz J, Zeng Y, et al. (2014) Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. *Proceedings of the National Academy of Sciences* 111: 1114–1119.
6. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, et al. (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. *Cancer discovery* 3: 761–769. doi: [10.1158/2159-8290.CD-13-0103](https://doi.org/10.1158/2159-8290.CD-13-0103) PMID: [23619167](https://pubmed.ncbi.nlm.nih.gov/23619167/)
7. Darnell J, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 264: 1415–1421. PMID: [8197455](https://pubmed.ncbi.nlm.nih.gov/8197455/)
8. Yu C-L, Meyer DJ, Campbell GS, Lerner AC, Carter-Su C, et al. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. *Science* 269: 81–83. PMID: [7541555](https://pubmed.ncbi.nlm.nih.gov/7541555/)
9. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, et al. (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. *Molecular and cellular biology* 18: 2545–2552. PMID: [9566874](https://pubmed.ncbi.nlm.nih.gov/9566874/)
10. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999) Stat3 as an oncogene. *Cell* 98: 295–303. PMID: [10458605](https://pubmed.ncbi.nlm.nih.gov/10458605/)
11. Yu H, Jove R (2004) The STATs of cancer—new molecular targets come of age. *Nature Reviews Cancer* 4: 97–105. doi: [10.1038/nrc1275](https://doi.org/10.1038/nrc1275) PMID: [14964307](https://pubmed.ncbi.nlm.nih.gov/14964307/)
12. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, et al. (2013) TPCA: a resource for cancer functional proteomics data. *Nature methods* 10: 1046–1047.
13. Peyser N, Freilino M, Wang L, Zeng Y, Li H, et al. (2015) Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. *Oncogene*.
14. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. *Proceedings of the National Academy of Sciences* 100: 9440–9445.
15. Dabney A, Storey JD, Warnes G (2010) qvalue: Q-value estimation for false discovery rate control. R package version 1.
16. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitz A, et al. (2006) Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. *International journal of cancer* 118: 2147–2157. doi: [10.1002/ijc.21514](https://doi.org/10.1002/ijc.21514) PMID: [16331601](https://pubmed.ncbi.nlm.nih.gov/16331601/)
17. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, et al. (2015) COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic acids research* 43: D805–D811. doi: [10.1093/nar/gku1075](https://doi.org/10.1093/nar/gku1075) PMID: [25355519](https://pubmed.ncbi.nlm.nih.gov/25355519/)

18. Coppo P, Flamant S, Mas VD, Jarrier P, Guillier M, et al. (2006) BCR–ABL activates STAT3 via JAK and MEK pathways in human cells. *British journal of haematology* 134: 171–179. doi: [10.1111/j.1365-2141.2006.06161.x](https://doi.org/10.1111/j.1365-2141.2006.06161.x) PMID: [16846476](https://pubmed.ncbi.nlm.nih.gov/16846476/)
19. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *New England Journal of Medicine* 344: 1038–1042. doi: [10.1056/NEJM200104053441402](https://doi.org/10.1056/NEJM200104053441402) PMID: [11287973](https://pubmed.ncbi.nlm.nih.gov/11287973/)
20. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. *New England Journal of Medicine* 344: 1031–1037. doi: [10.1056/NEJM200104053441401](https://doi.org/10.1056/NEJM200104053441401) PMID: [11287972](https://pubmed.ncbi.nlm.nih.gov/11287972/)
21. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. *The Journal of clinical investigation* 117: 3846. doi: [10.1172/JCI31871](https://doi.org/10.1172/JCI31871) PMID: [18060032](https://pubmed.ncbi.nlm.nih.gov/18060032/)
22. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA (2006) Signal transducer and activator of transcription 3 is required for the oncogenic effects of non–small-cell lung cancer–associated mutations of the epidermal growth factor receptor. *Cancer research* 66: 3162–3168. doi: [10.1158/0008-5472.CAN-05-3757](https://doi.org/10.1158/0008-5472.CAN-05-3757) PMID: [16540667](https://pubmed.ncbi.nlm.nih.gov/16540667/)
23. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science* 305: 1163–1167. doi: [10.1126/science.1101637](https://doi.org/10.1126/science.1101637) PMID: [15284455](https://pubmed.ncbi.nlm.nih.gov/15284455/)
24. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *The lancet oncology* 13: 239–246. doi: [10.1016/S1470-2045\(11\)70393-X](https://doi.org/10.1016/S1470-2045(11)70393-X) PMID: [22285168](https://pubmed.ncbi.nlm.nih.gov/22285168/)
25. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. *New England Journal of Medicine* 350: 2129–2139. doi: [10.1056/NEJMoa040938](https://doi.org/10.1056/NEJMoa040938) PMID: [15118073](https://pubmed.ncbi.nlm.nih.gov/15118073/)
26. Nallar SC, Kalakonda S, Lindner DJ, Lorenz RR, Lamarre E, et al. (2013) Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis. *Journal of Biological Chemistry* 288: 7930–7941. doi: [10.1074/jbc.M112.440610](https://doi.org/10.1074/jbc.M112.440610) PMID: [23386605](https://pubmed.ncbi.nlm.nih.gov/23386605/)
27. Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, et al. (2012) GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. *Journal of hepatology* 56: 184–191. doi: [10.1016/j.jhep.2011.07.018](https://doi.org/10.1016/j.jhep.2011.07.018) PMID: [21835143](https://pubmed.ncbi.nlm.nih.gov/21835143/)
28. Peyser ND, Du Y, Li H, Lui V, Xiao X, et al. (2015) Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. *PloS one* 10: e0135750. doi: [10.1371/journal.pone.0135750](https://doi.org/10.1371/journal.pone.0135750) PMID: [26267899](https://pubmed.ncbi.nlm.nih.gov/26267899/)
29. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, et al. (2003) Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. *Cancer research* 63: 2742–2746. PMID: [12782577](https://pubmed.ncbi.nlm.nih.gov/12782577/)
30. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 131: 1190–1203. doi: [10.1016/j.cell.2007.11.025](https://doi.org/10.1016/j.cell.2007.11.025) PMID: [18083107](https://pubmed.ncbi.nlm.nih.gov/18083107/)
31. Horvath S, Zhang B, Carlson M, Lu K, Zhu S, et al. (2006) Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. *Proceedings of the National Academy of Sciences* 103: 17402–17407.
32. Wang J, Zuo Y, Man Y-g, Avital I, Stojadinovic A, et al. (2015) Pathway and network approaches for identification of cancer signature markers from omics data. *Journal of Cancer* 6: 54. doi: [10.7150/jca.10631](https://doi.org/10.7150/jca.10631) PMID: [25553089](https://pubmed.ncbi.nlm.nih.gov/25553089/)
33. Qin HR, Kim H-J, Kim J-Y, Hurt EM, Klarmann GJ, et al. (2008) Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. *Cancer research* 68: 7736–7741. doi: [10.1158/0008-5472.CAN-08-1125](https://doi.org/10.1158/0008-5472.CAN-08-1125) PMID: [18829527](https://pubmed.ncbi.nlm.nih.gov/18829527/)
34. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, et al. (2010) STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. *Blood* 115: 2852–2863. doi: [10.1182/blood-2009-10-230060](https://doi.org/10.1182/blood-2009-10-230060) PMID: [20154216](https://pubmed.ncbi.nlm.nih.gov/20154216/)
35. Gan A-M, Butoi ED, Manea A, Simion V, Stan D, et al. (2013) Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-

- p protein pathways.
- Cell and tissue research*
- 351: 161–174. doi:
- [10.1007/s00441-012-1510-9](https://doi.org/10.1007/s00441-012-1510-9)
- PMID:
- [23086480](https://pubmed.ncbi.nlm.nih.gov/23086480/)
-
36. Gan AM, Pirvulescu MM, Stan D, Simion V, Calin M, et al. (2013) Monocytes and smooth muscle cells cross-talk activates STAT3 and induces resistin and reactive oxygen species and production. *Journal of cellular biochemistry* 114: 2273–2283. doi: [10.1002/jcb.24571](https://doi.org/10.1002/jcb.24571) PMID: [23606279](https://pubmed.ncbi.nlm.nih.gov/23606279/)
 37. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. *Proceedings of the National Academy of Sciences* 97: 4227–4232.
 38. Shah N, Trivedi T, Tankshali R, Goswami J, Jetly D, et al. (2005) Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. *The International journal of biological markers* 21: 175–183.
 39. Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS (2009) Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. *International journal of oncology* 34: 1209–1220. PMID: [19360334](https://pubmed.ncbi.nlm.nih.gov/19360334/)
 40. Jo M, Park MH, Kolipara PS, An BJ, Song HS, et al. (2012) Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. *Toxicology and applied pharmacology* 258: 72–81. doi: [10.1016/j.taap.2011.10.009](https://doi.org/10.1016/j.taap.2011.10.009) PMID: [22027265](https://pubmed.ncbi.nlm.nih.gov/22027265/)
 41. Gao L, Li F, Dong B, Zhang J, Rao Y, et al. (2010) Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells. *International Journal of Radiation Oncology* Biology* Physics* 77: 1223–1231.
 42. Lemmers B, Salmena L, Bidère N, Su H, Matysiak-Zablocki E, et al. (2007) Essential role for caspase-8 in Toll-like receptors and NFκB signaling. *Journal of Biological Chemistry* 282: 7416–7423. doi: [10.1074/jbc.M606721200](https://doi.org/10.1074/jbc.M606721200) PMID: [17213198](https://pubmed.ncbi.nlm.nih.gov/17213198/)
 43. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. *Cytokine & growth factor reviews* 21: 11–19.
 44. Guerrero-Preston R, Michailidi C, Marchionni L, Pickering C, Frederick M, et al. (2014) Key tumor suppressor genes inactivated by promoter methylation and somatic mutations in head and neck cancer. *Cancer Research* 74: 2482–2482.
 45. Marescalco MS, Capizzi C, Condorelli DF, Barresi V (2014) Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma. *Journal of Oral Pathology & Medicine* 43: 20–27.